Moderna is trading at $154.38, up +10.01%, after GSK’s decision to advance an mRNA flu vaccine into Phase III was interpreted as validation of Moderna’s broader mRNA platform.
- Investors are also sustaining enthusiasm from Moderna and Merck’s positive Phase III melanoma-vaccine results, which previously drove a major rally.
- Moderna is sharply outperforming the broader biotech sector and major indexes during the September 1, 2026 session.